Vertex and ono pharmaceutical announce strategic agreement to develop and commercialize povetacicept in japan and south korea

Boston & osaka, japan--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and ono pharmaceutical co., ltd. (otcmkts: ophly) today announced an exclusive collaboration and license agreement for the development and commercialization of vertex's povetacicept in japan and south korea. povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the baff (b cell activating factor) and april (a proliferation inducing ligand) cytokines with best-in-class potential b.
VRTX Ratings Summary
VRTX Quant Ranking